Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.

Luca MastorinoS SuscaC CaritiNiccolò SiliquiniA VerroneE StroppianaM OrtoncelliP DapavoSimone Ribero Pietro Quaglino

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

Anti-IL 23 and anti-IL 17 agents are not significantly different in terms of efficacy in bio-naive patients or as second-line therapy after failure with a biosimilar or originator adalimumab.

Keyphrases

end stage renal disease
rheumatoid arthritis
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
stem cells
systemic lupus erythematosus
bone marrow
patient reported outcomes
antiretroviral therapy
replacement therapy
smoking cessation
hidradenitis suppurativa